细胞色素P450 2C19、PON1及ABCB1基因多态性与氯吡格雷抵抗的关联分析

发布时间：2018-03-11 04:09

  本文选题：急性冠状动脉综合征　切入点：氯吡格雷　出处：《中国临床药理学杂志》2017年07期 　论文类型：期刊论文

【摘要】：目的观察经皮冠状动脉介入治疗(PCI)术后急性冠状动脉综合征(ACS)患者的细胞色素P450 2C19(CYP2C19)、PON1及ABCB1基因多态性与氯吡格雷抵抗的相关性。方法用荧光染色原位杂交方法检测175例进行PCI的ACS患者的CYP2C19*2、*3、*17、PON1及ABCB1基因型,用血栓弹力图法检测血小板聚集率。将血小板聚集率50%的患者列入氯吡格雷抵抗组,血小板聚集率≤50%列入氯吡格雷敏感组。结果 CYP2C19*2、*3基因为突变杂合型,氯吡格雷抵抗发生率较野生型显著升高,而CYP2C19*2/*2、*2/*3发生氯吡格雷抵抗的风险更高。PON1基因突变率为59.43%,其中突变纯合型为15.43%。ABCB1突变率为60.57%,其中突变纯合型为14.86%。两者虽然突变率较高,但都对氯吡格雷抵抗发生率没有明显影响。结论 PCI术后ACS患者的CYP2C19*2、*3基因突变显著影响氯吡格雷疗效,PON1及ABCB1基因则与其无显著相关性。
[Abstract]:Objective to investigate the association between cytochrome P450 2C19 CYP2C19 CYP2C19 PON1 and ABCB1 gene polymorphisms and clopidogrel resistance in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods fluorescence staining in situ hybridization was used to detect the relationship between cytochrome P450 2C19 and CYP2C19 PON1 and clopidogrel resistance. The genotypes of CYP2C192C192O2P01 and ABCB1 were detected in 175 ACS patients with PCI. Patients with platelet aggregation rate (50%) were included in clopidogrel resistance group and platelet aggregation rate 鈮，

本文编号：1596496